Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest Update

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) was the recipient of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 595,300 shares, an increase of 13.6% from the December 15th total of 523,900 shares. Approximately 7.5% of the company’s shares are short sold. Based on an average daily volume of 260,300 shares, the days-to-cover ratio is currently 2.3 days.

Citius Pharmaceuticals Stock Performance

CTXR stock traded up $0.04 during mid-day trading on Friday, hitting $3.30. 78,395 shares of the company were exchanged, compared to its average volume of 177,269. The firm has a market cap of $25.51 million, a P/E ratio of -0.55 and a beta of 1.30. Citius Pharmaceuticals has a 1-year low of $2.44 and a 1-year high of $26.75. The firm’s 50 day simple moving average is $4.09 and its 200 day simple moving average is $10.92.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. D. Boral Capital reissued a “buy” rating and set a $9.00 price target on shares of Citius Pharmaceuticals in a research report on Tuesday, January 7th. HC Wainwright reiterated a “buy” rating and set a $100.00 target price on shares of Citius Pharmaceuticals in a report on Tuesday, November 12th.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Point72 DIFC Ltd bought a new stake in shares of Citius Pharmaceuticals in the 2nd quarter valued at about $29,000. XTX Topco Ltd acquired a new position in Citius Pharmaceuticals during the third quarter worth approximately $47,000. Miller Investment Management LP raised its stake in Citius Pharmaceuticals by 99.3% in the third quarter. Miller Investment Management LP now owns 99,640 shares of the company’s stock valued at $50,000 after buying an additional 49,640 shares during the period. Virtu Financial LLC acquired a new stake in shares of Citius Pharmaceuticals in the third quarter valued at approximately $50,000. Finally, Cubist Systematic Strategies LLC bought a new position in shares of Citius Pharmaceuticals during the 2nd quarter worth approximately $69,000. Institutional investors and hedge funds own 16.88% of the company’s stock.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.